Disease · MONDO_0000521
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 19 of 19
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02879162 | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Phase 2 | 140 | 2025-02-17 | Advanced Rare Tumours | DURVALUMAB, TREMELIMUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03383692 | Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | Phase 1 | 40 | 2021-06-14 | Neoplasm Metastasis | ITRACONAZOLE, RITONAVIR, TRASTUZUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT04325828 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | Phase 2 | 31 | 2022-07-06 | Salivary Gland Neoplasms | APALUTAMIDE, GONADORELIN, GONADORELIN ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT05192642 | A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice | 368 | Solid Tumors Harboring NTRK Fusion | LAROTRECTINIB | Its record names the disease | ClinicalTrials.gov | ||
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Phase 2 | 215 | Solid Tumors Harboring NTRK Fusion | LAROTRECTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02776163 | Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas | Phase 2 | 107 | Salivary Gland Tumors, Head and Neck Cancer | DOCETAXEL, NEDAPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03132038 | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck | Phase 2 | 98 | Salivary Gland Carcinoma, Metastatic Cancer, Recurrent Cancer | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | Phase 2 | 88 | Advanced Salivary Gland Carcinoma | LEUPROLIDE, TRASTUZUMAB REZETECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02393820 | Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma | Phase 2 | 72 | Salivary Gland Carcinoma | PAZOPANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05694819 | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) | Phase 2 | 57 | Salivary Gland Cancer | DAROLUTAMIDE, GOSERELIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05727410 | Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma | Phase 2 | 50 | High-grade Salivary Gland Carcinoma | CISPLATIN, DOCETAXEL, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07579598 | ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma | Phase 2 | 40 | Adenoid Cystic Carcinoma of the Head and Neck, SBRT, Antibody-drug Conjugates | BECOTATUG VEDOTIN, SACITUZUMAB TIRUMOTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | Phase 2 | 39 | Salivary Gland Carcinoma, Precision Therapy | ABIRATERONE, ALPELISIB, BICALUTAMIDE, CADONILIMAB, CAMRELIZUMAB, CARBOPLATIN, DOCETAXEL, ENFORTUMAB VEDOTIN, FULVESTRANT, GOSERELIN, IVONESCIMAB, LENVATINIB, PACLITAXEL, PERTUZUMAB, PLATINUM, PYROTINIB, RIVOCERANIB, TRASTUZUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Phase 2 | 37 | Salivary Gland Cancer, HER2 Gene Mutation | TRASTUZUMAB EMTANSINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | Phase 2 | 35 | High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Poorly Differentiated Carcinoma, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer | TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06805617 | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers | Phase 2 | 35 | Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma | IVONESCIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05010629 | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Phase 2 | 32 | Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma | CARBOPLATIN, ELRAGLUSIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03942653 | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Phase 2 | 20 | Salivary Gland Carcinoma | GOSERELIN ACETATE, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04832438 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | Phase 2 | 0 | Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Salivary Gland Neoplasms | CARBOPLATIN, ELRAGLUSIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000521/trials